Home

ALAN W DUNTON

CIK 1304773 · Chief Exec Officer & President · last filed 2026-08-05

ALAN W DUNTON is a Chief Exec Officer & President who has filed 124 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for PTN, was dated Aug 5, 2026. Across all open-market trades the lifetime net is +$3.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $711.6K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$711.6K

Companies

6

Total Filings

124

Lifetime Open-Market Net

$3.59M

Filer Profile

Reported Address
VICURON PHARMACEUTICALS INC
455 S GULPH ROAD SUITE 305
KING OF PRUSSIA, PA 19406
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PTN Director 13,382 $11.80 $157.9K $4.02M 33 2026-08-05
CRMD Director 70,703 $7.83 $553.3K -$338.3K 16 2026-01-27
OGEN Director 854 $0.48 $408 -$186.7K 28 2025-12-15
MNOV Director — $1.81 — $0 4 2010-06-15
PANACOS PHARMACEUTICALS, INC. (PANC) Delisted Chief Exec Officer & President 240,865 — — $96.3K 8 2008-05-05
Adams Respiratory Therapeutics, Inc. (ARXT) Delisted Director 0 — — $0 7 2008-01-30

Recent Filings

124 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-05 PTN Trust (Z) — $0 EDGAR
2026-01-27 CRMD Grant (A) +30,453 $0 EDGAR
2026-01-02 CRMD Mixed — -$179.4K EDGAR
2025-12-30 CRMD Notice (144) −20,000 -$259.4K EDGAR
2025-12-15 OGEN Grant (A) — $0 EDGAR
2025-12-11 PTN Grant (A) +2,000 $0 EDGAR
2025-09-16 CRMD Mixed — -$95.8K EDGAR
2025-09-12 CRMD Notice (144) −10,000 -$130.9K EDGAR
2025-06-17 PTN Buy (P) +200 $4.00M EDGAR
2025-01-22 CRMD Grant (A) +25,000 $0 EDGAR
Showing 1–10 of 124
Page 1 of 13
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.